Electronic Supplementary Material (ESI) for RSC Advances. This journal is © The Royal Society of Chemistry 2016

Supporting Information

Self-assembling Ultrashort NSAID-Peptide Nanosponges: Multifunctional Antimicrobial and Anti-inflammatory Materials

Alice P. McCloskey, Sophie M. Gilmore, Jie Zhou, Emily R. Draper, Simon Porter, Brendan F. Gilmore, Bing Xu, Garry Laverty*

Ibuprofen-L-phenylalanine-L-phenylalanine-L-Lysine-L-Lysine-COOH (IbuFFKK). ¹H NMR (400 MHz, DMSO- d_6 , δ): 8.21-8.02 (m, J = 4.06, 4H; NH), 7.66 (s, J = 4.13, 4H; NH₂), 7.25-6.99 (m, J = 14.26, 14H; Ar H), 4.57-4.18 (m, J = 4.40, 4H, CHNH), 3.03 (q, J = 1.08, 1H; CHCH₃), 2.84-2.68 (m, J = 10.75, 8H; CH₂Ar, 2H; CH₂NH₂), 2.39 (d, J = 3.23, 3H; CH₃), 1.54-1.07 (m, J = 17.54, 2H; Ar CH₂CH(CH₃)₂, 1H; CH₂CH(CH₃)₂, 12H; CH₂), 0.86-0.83 (m, J = 6.51, 6H; CH₃). EIMS m/z (%): 756.46 (100) [M⁺], 757.46 (46.5) [M⁺+H]⁺, 758.46 (10.6) [M⁺+2H]⁺; (ESI) m/z: [M + H]⁺ calcd for C₄₃H₆₀N₆O₆, 756.99; found, 756.46.



Figure S1. ¹H NMR.spectra for IbuFFKK (C₂D₆OS, TMS standard, 400MHZ).

Indomethacin-L-phenylalanine-L-phenylalanine-L-Lysine-COOH (IndFFKK). ¹H NMR (400 MHz, DMSO-*d*₆, δ): 8.21-8.16 (m, *J* = 2.59, 1H; NH, 1H; Ar H), 7.63-7.55 (m, *J* = 4.16, 1H; Ar H, 2H; NH), 7.22-6.62 (m, *J* = 17.33, 14H; Ar H, 1H; NH, 4H; NH₂), 4.564.16 (m, *J* = 5.49, 4H; C*H*NH), 3.74-3.67 (m, *J* = 4.41, 3H; CH₃, 2H; CH₂CO), 3.03-2.68 (m, *J* = 14.50, 4H; C*H*₂NH₂, 4H; C*H*₂ Ar), 2.33 (s, *J* = 3.02, 3H; CH₃), 1.89-1.24 (m, *J* = 21.08, 12H; CH₂). EIMS *m*/*z* (%): 893.39 (100) [M⁺], 894.39 (51.9) [M⁺ − H], 895.38 (32) [M⁺ − 2H], 896.39 (16.6); (ESI) *m*/*z*: [M + H]⁺ calcd for C₄₉H₅₈ClN₇O₈, 894.47; found, 893.39.



Figure S2. ¹H NMR.spectra for IndFFKK (C₂D₆OS, TMS standard, 400MHZ).

Naproxen-L-phenylalanine-L-phenylalanine-L-Lysine-L-Lysine-COOH (NpxFFKK). ¹H NMR (400 MHz, DMSO- d_6 , δ): 8.22-8.04 (m, J = 5.53, 3H; NH, 2H; Ar H), 7.75-7.05 (m, J = 21.43, 14H; Ar H, 4H; NH₂), 4.50-3.71 (m, J = 6.20, 4H; CHNH, 1H; Ar CHCH₃), 2.98-2.68 (m, J = 9.97 4H; Ar CH₂, 4H; CH₂NH₂), 2.33 (s, J = 3.10, 3H; CH₃), 1.73-1.03 (m, J = 21.71, 12H; CH₂, 3H; CH₃). EIMS m/z (%): 780.42 (100) [M⁺], 781.42 (47.6) [M⁺ – H], 782.43 (11.1) [M⁺ – 2H]; (ESI) m/z: [M + H]⁺ calcd for C₄₄H₅₆N₆O₇, 780.97; found, 780.42.



Figure S3. ¹H NMR.spectra for NpxFFKK (C₂D₆OS, TMS standard, 400MHZ).



Figure S4. Gel inversion assay for IbuFFKK pH 7.4, H₂O primary vehicle. a) 0.5% w/v, b) 1.0% w/v, c) 1.5% w/v, d) 2.0% w/v.



Figure S5. Gel inversion assay for IbuFFKK pH 7.4, D₂O primary vehicle, a) 0.5% w/v, b) 1.0% w/v, c) 1.5% w/v, d) 2.0% w/v.



Figure S6. Gel inversion assay for IndFFKK pH 7.4, H₂O primary vehicle, a) 0.5% w/v, b) 1.0% w/v, c) 1.5% w/v, d) 2.0% w/v.



Figure S7. Gel inversion assay for NpxFFKK pH 7.4, H₂O primary vehicle, a) 0.5% w/v, b) 1.0% w/v, c) 1.5% w/v, d) 2.0% w/v



Figure S8. Cryo-SEM images of 2% w/v (a) IbuFFKK (D₂O), (b) IndFFKK (H₂O), (c) NpxFFKK (H₂O).



Figure S9. Cryo-SEM images of 2% w/v IbuFFKK (H₂O primary vehicle).



Figure S10. TEM images of 2% w/v (8900x) (a) IbuFFKK (D₂O), (b) IndFFKK (H₂O), (c)NpxFFKK (H₂O).



Figure S11. FTIR spectra displaying amide band of 2% w/v NSAID-peptides in deuterated solvents. Key: dotted line: IbuFFKK, dashed line: IndFFKK , full line: NpxFFKK.



Figure S12. FTIR spectra displaying amide band of 0.5-2% w/v NpxFFKK peptide. Key: dotted line: 0.5% w/v, dashed line: 1.5% w/v, full line: 2% w/v.



Figure S13. Logarithmic reduction in *S. epidermidis* (ATCC 35984) viable count (Log₁₀ CFU/mL) after 24 hour incubation with varying concentrations of NSAID-peptides. Results are displayed as a mean of six replicates. Key: grey column: IbuFFKK, striped column: IndFFKK, white column: NpxFFKK, dotted line: PBS control, black line: 2% w/v HPMC control. NS: no significant difference (P \geq 0.05), *: P<0.05, **: P<0.01 significant difference between Log₁₀ CFU/mL of NSAID-peptide and the negative control (PBS).



Figure S14. Logarithmic reduction in *E. coli* (ATCC 11303) viable count (Log₁₀ CFU/mL) after 24 hour incubation with varying concentrations of NSAID-peptides. Results are displayed as a mean of six replicates. Key: grey column: IbuFFKK, striped column: IndFFKK, white column: NpxFFKK, dotted line: PBS control, black line: 2% w/v HPMC control. NS: no significant difference (P \geq 0.05), *: P<0.05, **: P<0.01 significant difference between Log₁₀ CFU/mL of NSAID-peptide and the negative control (PBS).



Figure S15. IC_{50} values of NSAID-peptide and NSAIDs only molecules corresponding to inhibition of COX-1 (black column) and COX-2 (white column) enzymes. Selectivity (S) is defined as the ratio of the IC₅₀ values relative to COX-1: COX-2.



Figure S16. Percentage hemolysis of equine erythrocytes after 1 hour exposure to varying concentrations of NSAID-peptides. Key: striped: IbuFFKK, white: IndFFKK, grey: NpxFFKK, NS: no significant difference ($P \ge 0.05$) between the NSAID-peptide and the negative control (PBS).



Figure S17. Percentage toxicity of NCTC clone 929 (ATCC CCL 1) cells after 24 hour exposure to varying concentrations of NSAID-peptides. Toxicity is calculated by quantifying

LDH release. Key: striped: IbuFFKK, white: IndFFKK, grey: NpxFFKK, ns: no significant difference ($P \ge 0.05$) between the NSAID-peptide and the negative control (PBS).



Figure S18. LIVE/DEAD[®] stain results of NCTC 929 cells after 24 hours incubation with IbuFFKK. Scale bar represents 400 μ m, green staining indicates live cells, red staining indicates dead cells.



Figure S19. LIVE/DEAD[®] stain results of NCTC 929 cells after 24 hours incubation with IndFFKK. Scale bar represents 400 µm, green staining indicates live cells, red staining indicates dead cells.



Figure S20. LIVE/DEAD[®] stain results of NCTC 929 cells after 24 hours incubation with NpxFFKK. Scale bar represents 400 μ m, green staining indicates live cells, red staining indicates dead cells.



Figure S21. Quantitative cell counting analysis of LIVE/DEAD[®] stain after 24 hour exposure to varying concentrations of NSAID-peptides. Key: striped: IbuFFKK, white: IndFFKK, grey: NpxFFKK, ns: no significant difference ($P \ge 0.05$) between the NSAID-peptide and the negative control (PBS).